Shilpa Medicare has informed that the company has successfully completed phase 3 clinical studies of its novel product SMLNUD07 - Nor Ursodeoxycholic Acid (NorUDCA) tablets that is expected to revolutionise the treatment of patients suffering from Nonalcoholic Fatty Liver Disease (NAFLD).
The above information is a part of company’s filings submitted to BSE.